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Impact of Therapeutic Interventions on Survival of
Patients With Hepatic Hydrothorax
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Background/Purpose: Hepatic hydrothorax is an uncommon but important complication of liver cirrhosis.
The optimal management of this condition remains unclear. This retrospective study evaluated the impact
of therapeutic interventions on the outcome of patients with hepatic hydrothorax.
Methods: From August 1996 to March 2004, the medical charts of 52 patients with hepatic hydrothorax in
the National Taiwan University Hospital were reviewed. Treatment methods, outcome of interventions,
and survival time were described and analyzed.
Results: At the time of diagnosis, four patients were Child–Pugh class A, 20 were class B, and 28 were class
C. Twenty-eight (53.8%) patients received supportive care with thoracentesis for symptom relief. Among
the other 24 patients, 16 (30.8%) were treated by chemical pleurodesis, 14 (26.9%) underwent surgical
interventions, and six (11.5%) received both interventions. Intervention success, defined as resolution of
hydrothorax for at least 3 months after the procedure, was achieved in 37.5% and 42.9% of patients who
underwent chemical pleurodesis and surgery, respectively, with an overall success rate of 50%. The median
survival of all patients was 8.6 months (range, 0.2–77.6 months). The median survival of patients with 
intervention success (22.5 months) was significantly longer than those with intervention failure (5.4
months) and supportive care (6.3 months). Multivariate analysis showed that only intervention success
(p = 0.010, hazard ratio = 0.25) was an independent predictor of survival.
Conclusion: For patients with hepatic hydrothorax, aggressive medical or surgical intervention might improve
survival over supportive management, especially when resolution of hydrothorax can be maintained for at
least 3 months.
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Hepatic hydrothorax is defined as significant pleu-
ral effusion, usually > 500 mL, in a patient with
liver cirrhosis but no primary cardiac or pulmo-
nary disease.1–4 This is a relatively uncommon
complication that occurs in approximately 5% of
patients with cirrhosis.4 In recent years, hepatic
hydrothorax, along with hepatopulmonary syn-
drome and pulmonary hypertension, have been
©2010 Elsevier & Formosan Medical Association
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying, Tainan, and Departments of 2Internal Medicine
and 3Surgery, National Taiwan University Hospital, Taipei, Taiwan.
Received: August 3, 2009
Revised: October 27, 2009
Accepted: November 11, 2009
*Correspondence to: Dr Ping-Hung Kuo, Department of Internal Medicine, National Taiwan
University Hospital, 7 Chung Shan South Road, Taipei 100, Taiwan.
E-mail: kph712@ntuh.gov.tw
Survival in hepatic hydrothorax
J Formos Med Assoc | 2010 • Vol 109 • No 8 583
recognized as major pulmonary manifestations
of chronic liver disease and cirrhosis.5,6 Similar
to refractory ascites, hepatic encephalopathy, or
variceal hemorrhage, the presence of pleural ef-
fusion in patients with liver cirrhosis is usually
indicative of advanced cirrhosis.7
The development of hepatic hydrothorax 
involves a complex pathophysiological process.
The underlying mechanism for hepatic hydrotho-
rax is unclear, although many mechanisms have
been proposed, including hypoalbuminemia,
azygos vein hypertension, leakage from the tho-
racic duct, transdiaphragmatic lymphatic migra-
tion, and pressure-gradient-directed flow through
diaphragmatic defects.4 There is accumulating
evidence that diaphragmatic defects have a role
in cases of hepatic hydrothorax in which blebs or
fenestrations allow peritoneopleural communi-
cation.8–10 Based on these findings, many reported
treatments have been designed to eliminate the
cause of hepatic hydrothorax.
Despite numerous case reports that have 
described clinical features and treatments, the
optimal management of this condition remains
unknown. Liver transplantation is the treatment
of choice, but a donor is rarely available.11 Other
treatment options include repeated thoracen-
tesis, pleurodesis,12,13 placement of peritoneo-
venous shunts,14,15 placement of a transjugular
intrahepatic portosystemic shunt (TIPS),16–18
and surgical repair of the diaphragmatic leak.19
These are considered as temporary palliative
measures only, and also as a useful bridge to
transplantation.11
There are no guidelines on therapy of hepatic
hydrothorax based on good evidence; therefore,
most patients receive either supportive care or
chemical pleurodesis for symptomatic relief. The
optimal management, however, remains unclear
and few previous studies have systematically eval-
uated the effect of therapy on clinical outcome in
these patients. The aim of this study was to eval-
uate the impact of medical and surgical interven-
tions on the outcome of hepatic hydrothorax at a
tertiary hospital in Taiwan over an 8-year period.
Our hypothesis was that aggressive medical or
surgical interventions could improve the survival
of patients with hepatic hydrothorax.
Materials and Methods
Patients and data collection
A retrospective study was conducted in adult pa-
tients with a confirmed diagnosis of hepatic hy-
drothorax who were admitted to the National
Taiwan University Hospital, Taipei, Taiwan from
January 1996 to March 2004. A total of 52 patients
with complete medical records were included for
analysis. In all patients, the diagnosis was liver cir-
rhosis, as indicated by clinical and laboratory
findings, as well as by at least one imaging study
(abdominal sonography, computed tomography,
or magnetic resonance imaging). Chest radiogra-
phy on diagnosis showed no cardiomegaly or ac-
tive lung lesions except pleural effusion. All
patients received therapeutic thoracentesis, and
the results of cytology and microbial cultures of
pleural effusion samples were all negative. All pa-
tients were put on a sodium-restricted diet, and
diuretics and/or albumin were administered in-
termittently. Patients who underwent medical
and/or surgical interventions were classified as the
intervention group, and those who received sup-
portive care with thoracentesis for symptomatic
relief were classified as the supportive care group.
This research was approved by the Internal
Review Board of the National Taiwan University
Hospital.
Medical interventions
Medical interventions consisted of pleural drain-
age by chest tube thoracostomy followed by chem-
ical pleurodesis with intrapleural introduction of
sclerotic agents including minocycline, picibanil
and beta-iodine.
Surgical interventions
Surgical approaches included thoracoscopic di-
aphragmatic repair by application of pleural flap
and mesh onlay reinforcement, direct suture repair
via video-assisted thoracoscopic surgery (VATS),
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Denver shunt placement, and pleurodectomy. The
details of the pleural flap and mesh onlay method
have been previously reported.20
Supportive care
Patients in this group received intermittent tho-
racentesis for symptomatic relief only.
Outcome of interventions
Intervention success was defined as symptomatic
relief and the absence of thoracentesis for a min-
imum of 3 months after the procedure. Patients
who underwent medical or surgical interventions
but did not meet the criteria of intervention suc-
cess were considered as intervention failures.21,22
The survival time was measured from the date of
diagnosis of hepatic hydrothorax.
Statistical analysis
Values are expressed as mean ± standard devia-
tion (continuous variables) or as a percentage of
the group of origin (categorical variables). We used
the Cox regression model to analyze the data.
Censoring was defined for those patients who died
during observation. For the outcome analysis, pa-
tients were categorized into intervention success,
intervention failure and supportive care groups. We
examined the association between intervention
success and survival adjusted by potential con-
founders, including age, sex, Child–Pugh class, and
presence of hepatocellular carcinoma (HCC). The
potential confounders were selected on the basis
of a demonstrated association with outcome of
patients with cirrhosis in prior epidemiological
studies.23 All of these were retained in the model
regardless of their statistical significance. The effects
of clinical variables on survival are presented as
relative risks with 95% confidence intervals. Only
variables with complete data were analyzed in
the study. Kaplan–Meier survival curves were con-
structed and the log-rank test was used to compare
the intervention outcomes. All tests were two-sided
and used a significance level of 0.05. The statisti-
cal analysis was performed using STATA statistical
software version 8.0 (Stata Corp., College Station,
TX, USA).
Results
The characteristics of the overall study popula-
tion are shown in Table 1. At the time of diagnosis,
four patients were diagnosed with Child–Pugh
class A, 20 with class B, and 28 with class C. The
etiology of liver cirrhosis was hepatitis B (n = 26),
hepatitis C (n=17), alcohol (n=3), primary biliary
Table 1. Characteristics of the study population*
Characteristic All patients (n = 52) Interventions (n = 24) Supportive care (n = 28)
Age (yr) 62.2 (12.6) 60.3 (11.6) 63.8 (13.4)
Sex, male:female 23:29 11:13 12:16
Child-Pugh class
Class A 4 (7.7) 2 (8.3) 2 (7.1)
Class B 20 (38.5) 10 (41.7) 10 (35.7)
Class C 28 (53.8) 12 (50.0) 16 (57.1)
Etiology of liver cirrhosis
HBV 26 (50.0) 11 (45.8) 15 (53.6)
HCV 17 (32.7) 9 (37.5) 8 (28.6)
Alcoholic 3 (5.8) 3 (12.5) 0 (0)
Miscellaneous 6 (11.5) 1 (4.2) 5 (17.9)
History of HCC 20 (38.5) 6 (25.0) 14 (50.0)
Death 41 (78.8) 16 (66.7) 25 (89.3)
*Data presented as n (%) or mean ± standard deviation. HBV = hepatitis B virus infection; HCV = hepatitis C virus infection; HCC =
hepatocellular carcinoma.
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cirrhosis (n = 4), autoimmune hepatitis (n = 1), or
cryptogenic (n = 1). Hydrothorax was right-sided
(n = 44), left-sided (n = 6), or bilateral (n = 2). Six
patients (11.5%) had isolated hepatic hydrothorax
without demonstrable ascites. There was a higher
incidence of HCC in patients who received sup-
portive treatment only. Levels of protein and lactate
dehydrogenase in the pleural fluids were 1.36 ±
0.84 g/dL and 150.2 ± 74.7 U/L, respectively. HCC
was diagnosed in 38.5% of these patients.
Medical and surgical interventions
The intervention methods and clinical response of
the intervention group are summarized in Table 2.
Twenty-four patients underwent either chemical
pleurodesis only (n = 10), surgery only (n = 8), or
both (n = 6). The sclerotic agents used for pleuro-
desis included minocycline only (n = 8), picibanil
only (n = 1), minocycline + picibanil (n = 6), or
minocycline + picibanil + beta-iodine (n = 1). For
surgical interventions, the procedures included
thoracoscopic diaphragmatic repair using pleural
flap with mesh onlay reinforcement (n = 7), di-
rect suture repair via VATS (n = 3), Denver shunt
placement (n = 2), and pleurodectomy (n = 2). The
success rates of chemical pleurodesis only, sur-
gery only and both were 40%, 37.5% and 83.3%,
respectively, with an overall response rate of 50%.
Outcome of interventions
Outcome was successful in six patients treated with
chemical pleurodesis and in six treated with surgi-
cal intervention. Among the 12 patients with in-
tervention failure, five were totally unresponsive
to the intervention, three died within 3 months
because of other cirrhosis-related complications,
Table 2. Treatment methods and response of the
intervention population
Treatment
Response, n (%)
Success Failure
Pleurodesis only (n = 10) 4 (40.0) 6 (60.0)
Surgery only (n = 8) 3 (37.5) 5 (62.5)
Both (n = 6) 5 (83.3) 1 (16.7)
Total (n = 24) 12 (50.0) 12 (50.0)
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Figure. Kaplan–Meier survival curves of patients stratified
by intervention strategies and outcomes. Patients who
achieved intervention success had a higher rate of survival
than those received supportive care only and those with
intervention failure.
and four responded initially but suffered a recur-
rence of hepatic hydrothorax within 3 months
after the intervention.
The mortality rate was higher in the supportive
care group than in the intervention group during
the observation period (89.3% vs. 66.7%, p<0.05).
The median survival of all 52 patients was 8.6
months (range, 0.2–77.6 months). The survival of
patients with intervention success was significantly
longer (p = 0.002) than those with intervention
failure and supportive care (median survival =
22.5 months, 5.4 months, and 6.3 months, re-
spectively) (Figure). In univariate analysis, pres-
ence of HCC (p = 0.024) and intervention success
(p = 0.002) were significant predictors that af-
fected survival. The multivariate analysis showed
that only intervention success (p = 0.010, hazard
ratio = 0.25) was an independent predictor of
survival benefit (Table 3).
Discussion
This is believed to be the first study to examine the
impact of therapeutic interventions on the sur-
vival of patients with hepatic hydrothorax. Our
analysis after controlling for potential confound-
ing variables suggests that successful interven-
tion can improve survival in these patients.
Patients with hepatic hydrothorax have few
therapeutic options, and standardized evidence-
based treatment guidelines are lacking for patients
W.L. Liu, et al
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who fail to respond to diuretics. To the best of our
knowledge, only one previous study has shown
that aggressive intervention can have a survival
benefit in these patients.22 In that study, placement
of a TIPS resulted in clinical improvements in 84%
of patients with hepatic hydrothorax. All non-
responders died within 7 months, whereas 70%
of patients who responded to treatment survived
for the first year of follow-up.22 In our study, 50%
of patients achieved intervention success and re-
mained hydrothorax free. Patients with interven-
tion success had better survival than those with
intervention failure.
The increase in survival due to intervention
success in our patients with hepatic hydrothorax
could have resulted from the reduced risk of pul-
monary or pleural infections. Cirrhotic patients
with ascites are at risk for spontaneous bacterial
peritonitis; likewise, patients with hepatic hydro-
thorax might acquire spontaneous bacterial
empyema.24 Xiol et al studied the clinical course 
of 120 cirrhosis patients with hydrothorax and
reported that spontaneous bacterial empyema was
present in 13% on admission, and was associated
with a mortality rate as high as 20% during treat-
ment.25 Resolution of hydrothorax can eliminate
a possible infection source in those immunocom-
promised patients. In addition, about one in four
patients who underwent serial therapeutic thora-
centesis subsequently developed pneumotho-
rax.26 Elimination of hydrothorax can therefore
reduce potential complications that result from
repeated therapeutic thoracentesis.
Medical treatment with salt restriction and 
diuretics is the mainstay of therapy for hepatic
hydrothorax, but it only has a temporary effect in
one-third of patients.27 Several interventional
strategies have been commonly used in the man-
agement of hepatic hydrothorax, including tube
thoracostomy with chemical pleurodesis, repair
of defects in the diaphragm, and the placement
of a TIPS. Successful pleurodesis with tetra-
cycline via tube thoracostomy for two patients
with hepatic hydrothorax was first reported by
Falchuk et al in 1977.12 Lin et al also reported
hepatic hydrothorax in two patients who were
successfully treated with chemical pleurodesis with
minocycline.13 In our study, 16 patients received
tube thoracostomy with chemical pleurodesis, and
six (37.5%) were treated successfully. However,
the rates of fluid re-accumulation were very high.
Thoracoscopic or VATS pleurodesis might increase
the success rate. Ferrante et al reported refractory
hepatic hydrothorax in 15 patients who received
VATS and talc pleurodesis, and 11 patients (73%)
achieved resolution of effusion in the first 30 days
after the procedure, with eight remaining asymp-
tomatic for a median follow-up of 5.5 months.28
Only three had recurrence between 45 and 60 days
after the procedures. Cerfolio et al performed a
retrospective review in 41 patients with refractory
hepatic hydrothorax who underwent VATS with
talc pleurodesis.29 Overall success was achieved
in 33 patients (80%) and only four experienced
recurrence.
Moroux et al reported the use of VATS to repair
diaphragmatic defects in addition to pleurodesis
in eight patients with refractory hepatic hydrotho-
rax.30 The hydrothorax resolved in six patients
(75%) treated with surgery. The mean follow-up
time was 7–36 months and there was no recurrence
of pleural effusion in any of the six patients who
Table 3. Univariate and multivariate analyses of survival variable in intervention and supportive groups
Variable
Univariate analysis Multivariate analysis
p HR (95% CI) p
Age 0.100 1.00 (0.97–1.02) 0.760
Child-Pugh class 0.290 1.25 (0.26–6.11) 0.780
Presence of HCC 0.024 1.17 (0.60–2.28) 0.650
Intervention success 0.002 0.25 (0.08–0.75) 0.010
HCC = Hepatocellular carcinoma; HR = hazard ratios; CI = confidence interval.
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responded. Milanez de Campos et al performed
thoracentesis followed by talc poudrage under tho-
racoscopy and repair of diaphragmatic defects in 18
patients with persistent hepatic hydrothorax.21 A
total of 21 procedures were performed and the pa-
tients were followed for 3 months. Only 10
(47.6%) of the procedures were effective and there
was recurrence in 43.7% of cases. In our study, 14
patients received surgical interventions, and six
(42.9%) were successfully treated. There was a
trend for a higher success rate among patients who
underwent surgical intervention as compared
with those who received chemical pleurodesis only
(42.9% vs. 37.5%). Further randomized con-
trolled trials, however, are required to confirm
whether surgical interventions improve survival
of patients with hepatic hydrothorax.
None of our patients underwent TIPS insertion
for hepatic hydrothorax during the study period.
Data in the literature on the effectiveness of TIPS
placement in the management of refractory he-
patic hydrothorax are impressive. This procedure
can lead to symptomatic improvement in 70–80%
of patients with refractory hydrothorax.16,18,22
Although TIPS insertion is considered the proce-
dure of choice for management of refractory vari-
ceal bleeding, its role in refractory ascites and
hepatic hydrothorax awaits further prospective
studies.31 Nevertheless, encephalopathy and shunt
occlusion are anticipated complications, which
occurred in 25% and 31% of TIPS patients, respec-
tively, in a large series.32 According to Rossle et al,
the TIPS procedure is probably one of the most
difficult interventions in these patients and its re-
sults clearly depend on the skills of the operator.33
There are also no reliable predictors for the suc-
cess of this technique.34 In our institution, expe-
rience with this technique has been disappointing,
and surgeons are hesitant to perform this proce-
dure in patients with hepatic hydrothorax. One
of the authors (Dr P.M. Hwang) of the present
paper has reported good results with pleural flap
and mesh onlay reinforcement.20
Some limitations of our study need to be 
addressed. First, our intervention group was 
not homogeneous and was based on several 
interventional approaches (including agents used
for pleurodesis, types of surgery, and sequence of
interventions). It is therefore difficult to determine
the optimal approach in these patients. Second,
we failed to identify factors that were predictive
of successful outcomes before therapeutic inter-
ventions. Although our study showed no survival
benefit in the intervention failure group, many
in this group reported improved quality of life and
reduced severity of dyspnea. Perhaps this is be-
cause many of them had an initial response to the
intervention and reduced pleural effusion before
hydrothorax recurred. From this perspective, it
seems reasonable to perform the intervention for
all patients with hepatic hydrothorax if their con-
dition permits. A further study with a prospective
protocol may resolve these problems.
In summary, our results imply that aggressive
medical or surgical interventions confer a sur-
vival advantage over supportive management in
patients with hepatic hydrothorax, especially
when resolution of hydrothorax lasts for a mini-
mum of 3 months after the procedure. In addi-
tion, surgical interventions should be considered
if hepatic hydrothorax is refractory to chemical
pleurodesis.
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